<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0375410</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5127</journal-id>
<journal-id journal-id-type="nlm-ta">J Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Pediatr.</journal-id>
<journal-title-group>
<journal-title>The Journal of pediatrics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3476</issn>
<issn pub-type="epub">1097-6833</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28285751</article-id>
<article-id pub-id-type="pmc">6754744</article-id>
<article-id pub-id-type="doi">10.1016/j.jpeds.2017.02.036</article-id>
<article-id pub-id-type="manuscript">NIHMS859426</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Androgen Treatment Effects on Motor Function, Cognition and Behavior in Boys with Klinefelter Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ross</surname>
<given-names>Judith L.</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kushner</surname>
<given-names>Harvey</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kowal</surname>
<given-names>Karen</given-names>
</name>
<degrees>P.A.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bardsley</surname>
<given-names>Martha</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Davis</surname>
<given-names>Shanlee</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reiss</surname>
<given-names>Allan L.</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tartaglia</surname>
<given-names>Nicole</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roeltgen</surname>
<given-names>David</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Thomas Jefferson University, Department of Pediatrics, Philadelphia, Pennsylvania, 19107</aff>
<aff id="A2"><label>2</label>A.I. DuPont Hospital for Children, Wilmington, Delaware, 19803, 19104, Shore Physicians Group, Somers Point, NJ 08244</aff>
<aff id="A3"><label>3</label>Biomedical Research Institute, Philadelphia, Pennsylvania, 19115</aff>
<aff id="A4"><label>4</label>University of Colorado School of Medicine, Dept. of Pediatrics, Aurora, Colorado 80045</aff>
<aff id="A5"><label>5</label>Department of Psychiatry, Stanford University, Palo Alto, CA 94305</aff>
<aff id="A6"><label>6</label>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</aff>
<author-notes>
<corresp id="CR1"><bold>AUTHOR FOR CORRESPONDENCE:</bold> Judith L. Ross, MD, Thomas Jefferson University, Sidney Kimmel Jefferson Medical College, Department of Pediatrics, 833 Chestnut St., Philadelphia, PA 19107 USA, Phone: +1 215 955 1648; <email>judith.ross@jefferson.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>21</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>9</month>
<year>2019</year>
</pub-date>
<volume>185</volume>
<fpage>193</fpage>
<lpage>199.e4</lpage>
<!--elocation-id from pubmed: 10.1016/j.jpeds.2017.02.036-->
<abstract id="ABS1">
<sec id="S1">
<title>Objectives</title>
<p id="P1">To examine the effects of early low-dose androgen on motor, cognitive, and behavioral function in prepubertal boys with Klinefelter syndrome (47,XXY).</p>
</sec>
<sec id="S2">
<title>Study design</title>
<p id="P2">Double-blind trial of 84 boys, ages 4–12 years, randomized to oxandrolone (Ox, 0.06 mg/kg daily, N=43) or placebo (Pl, N=41) for 24 months. Standardized assessments were performed at baseline and every 12 months for 24 months evaluating motor, cognitive, and behavioral function.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">The 24 month outcomes were better in the Ox vs. Pl group on one of five primary endpoints (motor function/strength): Bruininks Visual-Motor scale (P=0.005), without significant differences between the 2 groups for the other 4 components. Secondary analyses suggested improvement in the Ox vs. Pl group in the Anxiety/Depression (P=0.03) and Social Problems (P=0.01) scales on the Child Behavior Checklist, Anxiety (P=0.04) on the Piers Harris Self Concept Scale, and Interpersonal Problems (P=0.02) on the Children’s Depression Inventory, without significant differences in hyperactive or aggressive behaviors.</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P4">This double-blind, randomized trial demonstrates that 24 months of childhood low-dose androgen treatment in boys with KS benefited one of five primary endpoints (visual-motor function). Secondary analyses demonstrated positive effects of androgen on aspects of psychosocial function (anxiety, depression, social problems), without significant effects on cognitive function, hyperactive or aggressive behaviors.</p>
</sec>
<sec id="S5">
<title>Trial registration</title>
<p id="P5"><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>: <related-object document-id="NCT00348946" document-id-type="clinical-trial-number" id="RO1" source-id="ClinicalTrials.gov" source-id-type="registry-name" source-type="clinical-trials-registry"></related-object></p>
</sec>
</abstract>
<kwd-group>
<kwd>Klinefelter Syndrome</kwd>
<kwd>47,XXY Child</kwd>
<kwd>Androgen</kwd>
<kwd>Randomized Controlled Trial</kwd>
<kwd>Testicular function</kwd>
<kwd>Gonadal failure</kwd>
<kwd>United States</kwd>
<kwd>Longitudinal Studies</kwd>
<kwd>Sex Chromosome Disorders, sex chromosome aneuploidy</kwd>
<kwd>sex chromosome variations</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>